Coloplast advances its long-term strategy despite challenges on many fronts
The pandemic in China, inflation, bottlenecking, and more: Coloplast’s problems are many, but work to meet goals set in Strive25, the medtech firm’s long-term plan, is still ongoing.
by marketwire, translated by daniel pedersen
Coloplast is still engaged with its long-term strategy entitled Strive25, and notes progress in 2021/2022. However, challenges such as lockdowns in China due to Covid-19, inflation, bottlenecking, and a searing hot labor market are looming on the horizon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast raises prices to offset energy cost spikes
For subscribers
Coloplast struggles to meet demand due to silicone shortage
For subscribers
